Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:HARP

Harpoon Therapeutics (HARP) Stock Price, News & Analysis

Harpoon Therapeutics logo

About Harpoon Therapeutics Stock (NASDAQ:HARP)

Advanced Chart

Key Stats

Today's Range
$23.01
$23.01
50-Day Range
$22.34
$23.01
52-Week Range
$3.11
$23.21
Volume
N/A
Average Volume
1.52 million shs
Market Capitalization
$389.61 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive HARP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Harpoon Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

HARP Stock News Headlines

Does Merck Stock Have Room For Growth?
The stealth altcoin the financial world is underestimating
The Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should buy in this market, this token might just be it.
Umoja Biopharma Appoints Scott Myers as Chairman of its Board of Directors
See More Headlines

HARP Stock Analysis - Frequently Asked Questions

Harpoon Therapeutics, Inc. (NASDAQ:HARP) posted its quarterly earnings results on Monday, March, 27th. The company reported ($5.50) EPS for the quarter, missing the consensus estimate of ($4.70) by $0.80. The firm had revenue of $4.09 million for the quarter, compared to analyst estimates of $11.06 million. Harpoon Therapeutics had a negative trailing twelve-month return on equity of 893.55% and a negative net margin of 81.68%.

Harpoon Therapeutics shares reverse split on Tuesday, September 5th 2023.The 1-10 reverse split was announced on Tuesday, September 5th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, September 5th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Harpoon Therapeutics (HARP) raised $76 million in an IPO on Friday, February 8th 2019. The company issued 5,400,000 shares at $13.00-$15.00 per share. Citigroup and Leerink Partners served as the underwriters for the IPO and Canaccord Genuity and Wedbush PacGrow were co-managers.

Based on aggregate information from My MarketBeat watchlists, some other companies that Harpoon Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), CrowdStrike (CRWD), Arista Networks (ANET) and Adobe (ADBE).

Company Calendar

Last Earnings
3/27/2023
Today
8/02/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:HARP
CIK
1708493
Fax
N/A
Employees
53
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($8.76)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$67.73 million
Net Margins
-81.68%
Pretax Margin
-81.67%
Return on Equity
-893.55%
Return on Assets
-45.98%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
1.89
Quick Ratio
1.89

Sales & Book Value

Annual Sales
$37.34 million
Price / Sales
10.43
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.63 per share
Price / Book
14.12

Miscellaneous

Outstanding Shares
16,932,000
Free Float
14,054,000
Market Cap
$389.61 million
Optionable
Optionable
Beta
2.11

Social Links

7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

This page (NASDAQ:HARP) was last updated on 8/2/2025 by MarketBeat.com Staff
From Our Partners